Published in Cardiovascular Week, October 6th, 2003
Gennevois has held a number of top clinical positions with leading biotechnology and pharmaceutical companies, including Roche Bioscience, Chiron Vaccines, and Syntex Corporation.
At Corgentech, Gennevois will oversee the company's pivotal phase III clinical trial studying its lead product, CGT003, an E2F Decoy therapy to prevent graft failure following coronary artery bypass graft (CABG) surgery. This trial is being conducted at approximately 100 leading medical centers in the United States and will...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cardiovascular Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.